{"filing":{"accession_number":"0001193125-26-267550","cik":"0001657677","ticker":"PBLS","company_name":"Parabilis Medicines, Inc.","form":"8-K","filing_date":"2026-06-11","report_date":null,"primary_document":"ck0001657677-20260609.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1657677/000119312526267550/ck0001657677-20260609.htm"},"events":[{"id":5357,"run_id":4694,"accession_number":"0001193125-26-267550","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Parabilis entered into a Stock Purchase Agreement with Regeneron for a private placement of 4,166,666 shares at $18.00 per share, concurrent with the Company's IPO on June 11, 2026. The unregistered private placement under Section 4(a)(2) and Regulation D includes piggyback registration rights for Regeneron and dilutes existing shareholders' ownership.","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6287,"accession_number":"0001193125-26-267550","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Parabilis entered into a Stock Purchase Agreement with Regeneron for a private placement of 4,166,666 shares at $18.00 per share (90% of the $20.00 IPO price), concurrent with the Company's IPO. This is a classic dilutive equity issuance—an unregistered private placement to a strategic investor that increases share count and dilutes existing shareholders. The transaction closed on June 11, 2026, and includes piggyback registration rights for Regeneron, typical of PIPE-like arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:15.747549+00:00","company_name":"","ticker":null,"filing_date":""},{"id":6288,"accession_number":"0001193125-26-267550","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This disclosure describes an unregistered private placement of equity securities (\"Shares\") to Regeneron under Section 4(a)(2) of the Securities Act and Regulation D. The filing explicitly states the Shares were issued and sold in a Private Placement without registration, which is the hallmark of a dilutive issuance. Such transactions are material to investors as they increase share count and dilute existing shareholders' ownership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:15.747549+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":5358,"run_id":4694,"accession_number":"0001193125-26-267550","anchor_item_number":"5.03","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"summary":"Parabilis amended its certificate of incorporation and bylaws in connection with the completion of its IPO, authorizing new share classes and establishing standard governance procedures including stockholder meeting procedures, advance notice requirements, and director nomination procedures.","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-06-11","form":"8-K","submitted_at":null,"items":[{"id":6289,"accession_number":"0001193125-26-267550","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes routine amendments to the certificate of incorporation and bylaws in connection with the company's IPO completion. While the amendments authorize new share classes and establish standard governance procedures (stockholder meeting procedures, advance notice requirements, director nomination procedures), these are administrative corporate governance changes typical of post-IPO restructuring. They do not involve executive changes, financial restatements, material transactions, or other substantive business events that would affect a reasonable investor's assessment of the company's operations or financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:15.747549+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6287,"accession_number":"0001193125-26-267550","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Parabilis entered into a Stock Purchase Agreement with Regeneron for a private placement of 4,166,666 shares at $18.00 per share (90% of the $20.00 IPO price), concurrent with the Company's IPO. This is a classic dilutive equity issuance—an unregistered private placement to a strategic investor that increases share count and dilutes existing shareholders. The transaction closed on June 11, 2026, and includes piggyback registration rights for Regeneron, typical of PIPE-like arrangements.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:15.747549+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-06-11"},{"id":6288,"accession_number":"0001193125-26-267550","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This disclosure describes an unregistered private placement of equity securities (\"Shares\") to Regeneron under Section 4(a)(2) of the Securities Act and Regulation D. The filing explicitly states the Shares were issued and sold in a Private Placement without registration, which is the hallmark of a dilutive issuance. Such transactions are material to investors as they increase share count and dilute existing shareholders' ownership.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:15.747549+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-06-11"},{"id":6289,"accession_number":"0001193125-26-267550","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes routine amendments to the certificate of incorporation and bylaws in connection with the company's IPO completion. While the amendments authorize new share classes and establish standard governance procedures (stockholder meeting procedures, advance notice requirements, director nomination procedures), these are administrative corporate governance changes typical of post-IPO restructuring. They do not involve executive changes, financial restatements, material transactions, or other substantive business events that would affect a reasonable investor's assessment of the company's operations or financial condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-11T20:14:15.747549+00:00","company_name":"Parabilis Medicines, Inc.","ticker":"PBLS","filing_date":"2026-06-11"}]}